Julie A. Smith

President & Chief Executive Officer at E-Scape Bio, Inc.

Julie A. Smith

Julie A. Smith

President & Chief Executive Officer at E-Scape Bio, Inc.

Overview
Career Highlights

E-Scape Bio, Inc.
Horizon Pharmaceutical LLC
Nuredis, Inc.

RelSci Relationships

852

Number of Boards

7

Birthday

1971

Age

50

Relationships
RelSci Relationships are individuals Julie A. Smith likely has professional access to. A relationship does not necessarily indicate a personal connection.

Founder at Biotechnology Innovation Organization

Relationship likelihood: Strong

Chairman, President & Chief Executive Officer at Horizon Therapeutics Plc

Relationship likelihood: Strong

Partner at Corvus Pharmaceuticals, Inc.

Relationship likelihood: Strong

Executive Vice President & Chief Financial Officer at Horizon Therapeutics Plc

Relationship likelihood: Strong

Executive Chairman at Nitrome Biosciences, Inc.

Relationship likelihood: Strong

Executive Partner at OrbiMed Advisors LLC

Relationship likelihood: Strong

Director & Vice Chairman-Food Governing Body at Biotechnology Innovation Organization

Relationship likelihood: Strong

Venture Partner at OrbiMed Advisors LLC

Relationship likelihood: Strong

Co-Chair at Biotechnology Innovation Organization

Relationship likelihood: Strong

President & Chief Executive Officer at Exelixis, Inc.

Relationship likelihood: Strong

Paths to Julie A. Smith
Potential Connections via
Relationship Science
You
Julie A. Smith
President & Chief Executive Officer at E-Scape Bio, Inc.
Education
BS in Biological & Nutritional Science

Cornell is a privately endowed research university and a partner of the State University of New York. As the federal land-grant institution in New York State, they have a responsibility—unique within the Ivy League—to make contributions in all fields of knowledge in a manner that prioritizes public engagement to help improve the quality of life in our state, the nation, the world.

Career History
Vice President-Commercial
2006 - 2008

Jazz Pharmaceuticals, Inc. develops and markets pharmaceutical products. Its medical products include Xyrem, Erwinaze, vyxeos, and kidrolas. The company was founded by Bruce C. Cozadd in 2003 and is headquartered in Palo Alto, CA.

President & Chief Executive Officer
2012 - Current

Raptor Pharmaceuticals (NASDAQ: RPTP) is a commercial-stage, global biopharmaceutical company committed to developing and commercializing life-altering therapeutics for orphan diseases. Their focus is to help patients with rare, debilitating, and potentially fatal diseases by leveraging a deep understanding of cellular metabolic pathways to develop medicines that address serious unmet medical needs.

Product Manager
1996 - Prior

Bristol-Myers Squibb Company Our company has a strong legacy of innovation that began in New York in 1858 when Edward R. Squibb, M.D., founded a pharmaceutical company in Brooklyn, and in 1887 when two friends, William McLaren Bristol and John Ripley Myers purchased a struggling drug manufacturing firm in Clinton. Together, they laid the foundation for our company today — a global BioPharma leader that continues this legacy of innovation.

Boards & Committees
Member, Board of Directors
2020 - Current

Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. It offers a wide range of relevant tissues including the central nervous system, eye, kidney, and liver. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.

Director
2018 - Current

E-Scape Bio, Inc. a preclinical stage biopharmaceutical company. It focuses on the discovery and development of therapies to treat genetically defined, neurodegenerative diseases. The company was founded by Robert Mahley and Yadong Huang in 2015 and is headquartered in San Francisco, CA.

Independent Director
2016 - Current

Exelixis is a biopharmaceutical company committed to developing and commercializing small molecule therapies for the treatment of cancer. In advancing our first product, COMETRIQ, from discovery to market, we have established an effective and integrated infrastructure that encompasses the entire biopharmaceutical development continuum. We are committed to excellence in all aspects of our work and are dedicated to improving the care and outcome of cancer patients.

Member, Emerging Companies Section Governing Board
2016 - Current

Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers.

Transactions
Details Hidden

E-Scape Bio, Inc. raised money in a private placement transaction

Details Hidden

E-Scape Bio, Inc. raised money in a private placement transaction

Details Hidden

Horizon Pharmaceutical LLC issued USD Common Stock

Public Holdings
Restricted data only for RelSci Professional users.
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Julie A. Smith. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Julie A. Smith's profile does not indicate a business or promotional relationship of any kind between RelSci and Julie A. Smith.